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OBJECTIVES We compared in-hospital and one-year clinical outcomes in patients undergoing debulking
followed by stent implantation versus stenting alone for saphenous vein graft (SVG)
aortoostial lesions.
BACKGROUND Stent implantation in SVG aortoostial lesions may improve procedural and late clinical outcomes.
However, the impact of debulking before stenting in this complex lesion subset is unknown.
METHODS We studied 320 consecutive patients (340 SVG aortoostial lesions) treated with Palmaz-
Schatz stents. Debulking with excimer laser or atherectomy was performed in 133 patients
(139 lesions) before stenting (group I), while 187 patients (201 lesions) underwent stent
implantation without debulking (group II). Procedural success and late clinical outcomes were
compared between the groups.
RESULTS Overall procedural success (97.6%) was similar between the groups. Procedural complications
were also similar (2.2% for group I and 2.6% for group II). At one-year follow-up, target
lesion revascularization (TLR) was 19.4% for group I and 18.2% for group II (p 5 0.47).
There was no difference in cumulative death or Q wave myocardial infarction between the
groups. Overall cardiac event-free survival was similar (69% for group I and 68% for group II).
By Cox regression analysis, the independent predictors of late cardiac events were final lumen
cross-sectional area (CSA) by intravascular ultrasound (IVUS) (p 5 0.001) and restenotic
lesions (p 5 0.01). Similarly, final IVUS lumen CSA (p 5 0.0001) and restenotic lesions (p 5
0.006) were found to predict TLR at one year.
CONCLUSIONS These results suggest that, in most patients with SVG aortoostial lesions, debulking before
stent implantation may not be necessary. (J Am Coll Cardiol 2000;35:1560–8) © 2000 by
the American College of Cardiology
Treatment of saphenous vein graft (SVG) aortoostial lesions
by conventional balloon angioplasty or new devices (laser or
atherectomy) has been associated with suboptimal results,
frequent periprocedural complications and higher rates of
restenosis (1–3). These disappointing results can be attrib-
uted, in part, to the excessive residual stenosis and unyield-
ing plaque. Stents have been found to improve short- and
long-term outcomes compared with percutaneous translu-
minal coronary angioplasty (PTCA) or atherectomy when
used for aortoostial lesions (4–6). However, even with
stents the risk of restenosis remains high. It has been
suggested that debulking the atherosclerotic plaque or
altering the lesion compliance with atheroablative devices
before stent implantation may improve procedural and late
clinical outcomes in this complex lesion subset.
Thus, to determine the acute and late clinical outcomes
associated with stent implantation with or without prior
debulking for SVG aortoostial lesions, we evaluated proce-
dural success, major in-hospital complications and one-year
clinical outcomes in a large consecutive series of patients.
METHODS
Study population. The patient cohort included a consec-
utive series of 320 patients (340 SVG aortoostial lesions)
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Database treated with Palmaz-Schatz stent implantation
between September 1995 and March 1997. All patients
gave written informed consent approved by the Institu-
tional Review Board of the Washington Hospital Center
before the procedure. These patients represent the ma-
jority (.95%) of patients with SVG aortoostial lesions
treated during the study period, as the strategy was to
implant stents in all SVG aortoostial lesions, and only
patients with distal embolization and reduced flow did
not receive stents. Patients were divided into two groups
according to the type of intervention used. All indications
for stent use (planned elective use to improve acute
procedural safety and reduce late clinical events, provi-
sional use to treat suboptimal primary device results or
urgent use to treat abrupt or threatened closure) are
included in this study. Debulking with excimer laser (n 5
90), directional atherectomy (n 5 39) and transluminal
extraction atherectomy (n 5 10) was performed in 139
lesions before stenting (group I), and 201 lesions were
treated with stents alone (group II).
Baseline demographic characteristics and in-hospital
events were recorded by independent hospital chart
review. Clinical follow-up data were obtained by office
visits or serial telephone interviews by research nurses.
All records relevant to late clinical events (death, Q wave
myocardial infarction [MI] and any revascularization)
and target lesion revascularization were obtained and
evaluated by an independent adjudication committee. In
addition to target lesion revascularization, repeat revas-
cularization is also reported per patient (as any repeat
revascularization) and includes all target lesion and target
vessel revascularizations.
Definitions. Procedural success was defined as a final
diameter stenosis ,50% in the absence of major in-
hospital complications (death, Q wave MI and coronary
artery bypass surgery [CABG]). A diagnosis of Q wave
MI was made when there was documentation of patho-
logical Q waves (.0.04 s) on an electrocardiogram
(ECG) in conjunction with elevation of creatinine phos-
phokinase greater than twice the upper limit of normal.
Non-Q wave MI was defined as creatinine kinase-MB
(CK-MB) enzyme elevation $5 times the upper limit of
normal in the absence of new pathological Q waves.
Degenerated SVG were those with ectasia or lumen
irregularity comprising $50% of the SVG shaft length.
Ectasia was a lumen .20% larger than the user-defined
reference segment. For the purpose of this study, ostial
lesions were defined as within 3 mm of the proximal
anastomosis.
Stent types and deployment technique. The types of
stents used were either coronary (n 5 114, 28.7%) or
“biliary” Palmaz-Schatz (n 5 282, 71.3%) (Johnson and
Johnson Interventional Systems, Warren, New Jersey).
Stent implantation procedures were performed using tech-
niques described previously (7,8). Coronary stents were used
for vessels #4 mm and a larger biliary version was selected
for vessels .4 mm in diameter. The lesion was crossed with
a 0.014 in floppy or extrasupport guide wire, and either prior
balloon angioplasty or atheroablation was performed before
stent implantation. Adjunct high-pressure PTCA was per-
formed after initial stent deployment (14 to 16 atms) in all
cases. Intravascular ultrasound (IVUS) imaging was per-
formed in 270 (79.4%) lesions pretreatment, poststent
implantation and postadjunct PTCA. Optimal stent im-
plantation was carefully monitored using an interactive
technique with prespecified IVUS end points and additional
high-pressure inflations if needed. The IVUS was used to
optimize stent apposition, expansion (minimal stent area
$80% of the distal reference lumen area) and lesion
coverage. In addition, IVUS enabled the detection of
outflow obstruction and residual dissection at stent margins.
All patients were pretreated with aspirin and continued
their standard antianginal therapy. A bolus of 10,000 U of
intravenous heparin was given after insertion of femoral
arterial sheath. After the initial administration, a repeat
bolus of 5,000 U was given to maintain the activated
clotting time (ACT) .300 s, if necessary. Heparin was
stopped immediately after the procedure, and the sheath
was removed when the ACT was ,150 s. All patients
received ticlopidine at a dose of 250 mg twice daily for four
weeks. Abciximab (Centocor, Malvern, Pennsylvania) was
used in ,5% of patients. Emboli containment devices were
not used in any patients.
Atheroablation. Device selection was based on vessel size,
preprocedural lesion morphology (lesion eccentricity, ulcer-
ation, degeneration, irregularity, calcification and thrombus)
and the absence of clinical contraindications at the discre-
tion of the operator. Directional atherectomy (Devices for
Vascular Intervention, Redwood City, California) was cho-
sen for eccentric lesions located in the nondegenerated SVG
$3 mm in diameter (n 5 39, 28%). The procedure was
performed according to the previously described technique
(9). Most commonly a 7F atherectomy device was used. In
Abbreviations and Acronyms
ACT 5 activated clotting time
CABG 5 coronary artery bypass surgery
CK-MB 5 creatinine kinase-MB
CSA 5 cross-sectional area
ECG 5 electrocardiogram
EEM 5 external elastic membrane
IVUS 5 intravascular ultrasound
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
P 1 M 5 plaque plus media
PTCA 5 percutaneous transluminal coronary
angioplasty
SVG 5 saphenous vein graft
TLR 5 target lesion revascularization
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the event of residual stenosis .30%, localized dissection or
intimal flap, a larger device was used to treat the residual
stenosis.
The Transluminal Extraction Atherectomy (TEC; Inter-
Ventional Technologies, San Diego, California) was used
for ostial lesions (n 5 10, 7.1%) in degenerated SVG or
thrombus containing lesions. It was performed by the
methods described previously (10).
The excimer laser angioplasty (Spectranetics/Advanced
Interventional System, Colorado Springs, Colorado) was
selected for smaller or degenerated SVG (n 5 90, 64.7%).
The ELCA procedure was performed as described else-
where (11). In brief, the range of the laser fiber catheter used
was 1.7 mm to 2.0 mm. Energy densities ranged from 25 to
65 mJ/mm2 (mean 57.9 6 5.4 mJ/mm2), and the number of
pulses ranged from 30 to 1,880 (mean, 339 6 352). A single
laser pass technique was used in most of the cases.
Adjunct balloon angioplasty was performed in all
atheroablation cases before stent implantation to ensure
adequate stent expansion.
Angiographic analysis. All cineangiograms were ana-
lyzed with the use of a computer-assisted, automated
edge-detection algorithm (ARTREK, Quantitative Car-
diac System, Ann Arbor, Michigan) by a core angio-
graphic laboratory that was blinded to the clinical out-
come. With the outer diameter of the contrast filled
catheter as the calibration standard, reference and mini-
mal lumen diameters (MLDs) were determined before
and after stent implantation, and post final PTCA from
multiple projections and the results from the “worst” view
were recorded. Based upon these measurements, percent
diameter stenoses were determined. Standard morpho-
logic criteria were used for the identification of lesion
length (“shoulder-to-shoulder”), eccentricity, irregularity,
fluoroscopic calcification and ulceration.
IVUS imaging protocol. Intravascular ultrasound studies
were performed with the Boston Scientific Corporation/
Cardiovascular Imaging System. This system incorporated a
single-element 30-MHz transducer and an angled mirror
mounted on the tip of a flexible shaft that was rotated at
1,800 rpm within a 3.2F short monorail polyethylene
imaging sheath to form planar cross-sectional images in real
time. All IVUS studies were performed after administration
of 0.2 mg of intragraft nitroglycerin. The ultrasound cath-
eter was advanced ’10 mm beyond the target lesion, and a
slow imaging run (using automated transducer pullback at
0.5 mm/s) was performed from beyond the target lesion to
the aortoostial junction. A number of cross-sectional mea-
surements were made, and validation of these measurements
by IVUS has been reported previously (12,13). By using
computerized planimetry (TapeMeasure, Indec Systems,
Mountain View, California), lesion site and reference seg-
ment external elastic membrane (EEM) cross-sectional area
(CSA) and lumen CSA were measured. Because media
thickness cannot be measured accurately, plaque plus media
(P 1 M) CSA (EEM CSA minus lumen CSA) was used as
a measure of atherosclerotic plaque. Plaque burden (cross-
sectional narrowing) was calculated as the P 1 M CSA
divided by the EEM CSA. When the atherosclerotic plaque
encompassed the catheter, the lumen was assumed to be the
size of the imaging catheter. The reference segment selected
was the most visually normal cross section within 10 mm
distal to the lesion.
Statistical analysis. Statistical analysis was performed us-
ing StatView 4.5 or SAS (14) (both SAS Institute Inc, Cary,
North Carolina). Categorical data are presented as percent
frequency and compared between groups by chi square
statistics. Continuous variables are presented as mean 6 one
standard deviation, and comparison between the groups was
performed using unpaired t test. Cox (15) proportional
hazard regression analysis was used to determine indepen-
dent correlates of target lesion revascularization (TLR) and
late cardiac events. Survival curves were constructed by
Kaplan Meier method and displayed using the SAS
LIFETEST procedure. The Wilcoxon log rank test was
used for survival comparison between groups. A p value
#0.05 was considered statistically significant.
RESULTS
Baseline demographics. The baseline characteristics of all
treated patients are listed in Table 1. The groups were well
matched except for a higher incidence of previous MI in the
stent alone group and a trend for more diabetic patients in
the debulking and stent group. The treated grafts were
relatively old with an average graft age of 96.3 6 58.6
months.
Angiographic analysis and procedural characteristics.
Lesion characteristics and quantitative angiographic
measurements are presented in Tables 2 and 3. Eccentric
lesions were more frequent in group I as compared with
group II (63.6% vs. 46.8%, p 5 0.02). The prevalence of
degenerated SVG, ulceration, thrombus containing and
restenotic lesions was similar for the two groups, most
likely related to the small sample size. Likewise, there
was no difference in the average pretreatment and post-
treatment angiographic reference diameter. Interestingly,
despite a smaller MLD and greater baseline diameter
stenosis in group I, the final MLD was greater and
diameter stenosis was lower.
A total of 396 stents were deployed in 320 patients with
340 lesions. The mean number of stents per lesion was
1.17 6 0.45. In 289 (85.0%) lesions, a single stent was used,
and 51 (15.0%) lesions were treated with two stents.
Average balloon size was 4.36 6 0.79, and mean final
inflation pressure was 15.1 6 4.2. The average balloon-to-
artery ratio used for final stent expansion was 1.30 6 0.25.
IVUS analysis. Quantitative IVUS findings are presented
in Table 4. Preintervention, lesions treated with plaque
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debulking and stenting had smaller MLD and lumen CSA.
Conversely, these lesions had larger P 1 M CSA and
greater plaque burden (Table 4). Postintervention, these
lesions had lesser plaque burden as compared with lesions
treated with stents alone.
Procedural results. Overall procedural success was high
and similar for the two groups (Table 5). Similarly com-
bined major in-hospital complications (death, Q wave MI
and emergent CABG) did not differ significantly between
the groups (2.2% vs. 2.6%, p 5 0.24). Likewise, the
Table 1. Baseline Characteristics of the Study Population
Group I
Debulking and Stents
(n 5 133 Patients)
Group II
Stents Alone
(n 5 187 Patients) p Value
Age (yrs) 67 6 9 66 6 9 0.89
Male gender (%) 82.7 82.3 0.91
Unstable angina (%) 81.5 77.5 0.39
Diabetes mellitus (%) 37.0 28.0 0.06
Insulin dependent (%) 13.3 9.5 0.28
Hypercholesterolemia (%) 68.1 76.7 0.08
Systemic hypertension (%) 69.6 62.6 0.19
Previous MI (%) 54.6 66.3 0.03
Smoking (%) 67.5 64.9 0.34
Family history for CAD (%) 60.5 62.5 0.75
LVEF (mean 6 SD) 0.39 6 0.13 0.39 6 0.14 0.92
Graft age (months) 94.2 6 59.7 97.8 6 58.2 0.58
CAD 5 coronary artery disease; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
Table 2. Qualitative and Quantitative Angiographic Lesion Characteristics
Group I
Debulking and Stents
(n 5 139 Lesions)
Group II
Stents Alone
(n 5 201 Lesions) p Value
Lesion characteristics
Eccentricity (%) 46.8 63.6 0.02
Restenotic (%) 24.0 27.6 0.48
Thrombus (%) 8.9 10.0 0.79
SVG degeneration (%) 36.0 36.5 0.94
Ulceration (%) 16.5 16.4 0.97
Calcification (%) 1.3 2.8 0.64
Lesion length $10 mm (%) 32.5 29.4 0.65
Aneurysm (%) 1.7 2.0 0.91
Procedural complications
Distal embolization (%) 1.3 1.9 0.87
Abrupt closure (%) 0.0 0.0 —
Dissection (%) 1.3 0.0 0.43
Perforation (%) 1.9 0.0 0.50
No reflow (%) 3.4 2.2 0.91
Quantitative measurements:
Reference diameter (mm)
Preintervention 3.49 6 0.70 3.47 6 0.76 0.87
Postintervention (final) 3.56 6 0.78 3.51 6 0.65 0.58
Lesion MLD (mm)
Preintervention 1.01 6 0.61 1.19 6 0.66 0.05
Postintervention (final) 3.43 6 0.76 3.21 6 0.70 0.05
Diameter stenosis (%)
Preintervention 71 6 17 65 6 18 0.05
Postintervention (final) 2.7 6 17 7.5 6 17 0.01
MLD 5 minimal luminal diameter; SVG 5 saphenous vein graft.
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incidence of subacute stent thrombosis, vascular complica-
tions and the need for repeat in-hospital target lesion
angioplasty was similar for both groups. The presence of any
CK-MB enzyme elevation postintervention was found in
34.1% vs. 31.0% (p 5 0.55), and non-Q wave MI (CK-MB
$5 times normal occurred in 18.2% vs. 18.5% (p 5 0.94) of
the patients. Intravascular ultrasound guidance was used
more frequently in patients who underwent atheroablation
before stenting as compared with patients who were treated
with stents alone (87.8% vs. 73.6%, p 5 0.002). The
periprocedural use of abciximab was similar for both groups
(2.9% for debulking and stenting vs. 4.7% for stents alone,
p 5 0.41). A representative procedural result before and
after laser treatment and stent implantation to treat an ostial
SVG lesion is shown in Figure 1.
Late clinical outcomes. Clinical follow-up up to one year
was available in 130 (97.7%) patients in group I and 181
(96.7%) patients in group II (Table 5). There was no
difference in late mortality or Q wave MI between the two
groups. Overall TLR at one year was 19.4% for patients
treated with debulking and stenting and 18.2% for patients
treated with stenting alone (p 5 0.47). The rate of any
repeat revascularization was also similar for both groups
(23.7% vs. 19.9, p 5 0.39). Actuarial event free survival
curves for any cardiac events (death, Q wave MI, angio-
Table 3. Interventional Procedures in All Lesions
Group I
Debulking and Stents
(n 5 139 Lesions)
Group II
Stents Alone
(n 5 201 Lesions) p Value
Procedure type




Excimer laser (%) 64.7 0.0 —
Stent types
Coronary Palmaz-Schatz (%) 26.6 29.3 0.22
Biliary, Palmaz-(Schatz) (%) 73.4 70.7 0.39
Stent/lesion 1.14 6 0.41 1.19 6 0.48 0.25
Final balloon size (mm) 4.36 6 0.80 4.36 6 0.78 0.98
Balloon/artery ratio 1.31 6 0.28 1.30 6 0.23 0.69
Maximum inflation pressure (atm) 14.8 6 4.1 15.3 6 4.2 0.48
IVUS guidance (%) 87.8 73.6 0.002
IVUS 5 intravascular ultrasound.
Table 4. Pre- and Postintervention IVUS Analysis
Group I
Debulking and Stents
(n 5 139 Lesions)
Group II
Stents Alone
(n 5 201 Lesions) p Value
Preintervention
Reference (distal)
Lumen CSA (mm2) 7.0 6 3.0 8.5 6 5.0 0.61
EEM CSA (mm2) 20.7 6 6.3 21.3 6 7.1 0.71
P 1 M CSA (mm2) 13.6 6 4.9 12.9 6 4.7 0.45
Lesion site
Lumen CSA (mm2) 2.4 6 1.7 3.4 6 1.8 0.006
EEM CSA (mm2) 19.4 6 10.8 18.0 6 6.2 0.84
MLD (mm2) 1.4 6 0.45 1.7 6 0.51 0.01
P 1 M CSA (mm2) 18.4 6 9.2 15.6 6 8.3 0.01
Plaque burden (%) 87.9 6 9.0 81.9 6 8.2 0.008
Postintervention
Lesion site
Lumen CSA (mm2) 11.9 6 7.9 10.2 6 3.5 0.31
MLD (mm2) 3.2 6 0.50 3.1 6 0.6 0.21
EEM CSA (mm2) 20.5 6 9.7 19.9 6 8.8 0.36
Plaque burden (%) 57.6 6 10.5 64.9 6 11.0 0.01
CSA 5 cross-sectional area; EEM 5 external elastic membrane; IVUS 5 intravascular ultrasound; MLD 5 minimal lumen
diameter; P 1 M 5 plaque 1 media.
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plasty or CABG) and for TLR at one-year follow-up are
shown in Figure 2. Event-free survival was similar in both
groups for both end points (p 5 0.48 for any event and p 5
0.12 for TLR).
Cox regression analysis was performed to determine the
independent correlates of any adverse cardiac events and
TLR at one-year follow-up. The following variables were
entered into the multivariable model: age, gender, graft age,
diabetes, hypertension, previous history of MI, types of
stents, prestent atheroablation, MLD before and after
intervention, preintervention and final reference lumen
diameter, plaque burden and final lumen CSA by IVUS.
The independent predictors of late cardiac events were: final
IVUS lumen CSA (relative risk: 0.61 CI: 0.47–0.78, p 5
0.001) and restenotic lesions (relative risk: 1.67, CI: 1.11–
2.49, p 5 0.01). Similarly, final IVUS lumen CSA (relative
risk: 0.61, CI: 0.62–0.89, p 5 0.0001) and restenotic lesions
(relative risk: 1.94, CI: 1.20–3.14, p 5 0.006) were found to
predict TLR at one year.
DISCUSSION
This study shows that patients with SVG aortoostial lesions
treated with stent implantation with or without prior
atheroablation have: 1) similar in-hospital procedural results
and major complications, and 2) similar one-year cardiac
events, including TLR and any repeat revascularization. In
this large patient cohort, we also identified independent
predictors of TLR and late cardiac events. Lumen CSA by
IVUS and restenotic lesions were found to predict both
TLR and adverse cardiac events at one year. Interestingly, in
none of these analyses did prestent atheroablation predict
TLR or adverse cardiac end points.
Treatment of SVG aortoostial lesions. Overall procedural
success rate of balloon angioplasty in SVG varies between
84% and 92% (1,2). Procedural success is lower in aortoos-
tial location compared with nonostial locations (1,2). Con-
ventional balloon angioplasty is frequently unsuccessful in
this location due to greater elastic recoil. Several investiga-
tors have demonstrated that stent use in SVG aortoostial
lesions is associated with high procedural success and low
complication rates (16–18). Furthermore, in a retrospective
comparison of stenting and balloon angioplasty for SVG
aortoostial lesions, Brener et al. (4) have shown that patients
in the stent group had a lower incidence of composite end
points of death, MI and repeat revascularization (23% vs.
45%, p , 0.001) at one-year follow-up (12). Likewise,
Rocha-Singh et al. (6) reported a 93% procedural success
rate and 27% restenosis rate with Palmaz-Schatz stent
implantation in ostial SVG lesions. In another study involv-
ing stent implantation in SVG aortoostial in patients with
unstable angina, Rechavia et al. (5) have shown high
immediate success and low 30-day and long-term event
rates.
However, no study has addressed the issue of whether
atheroablation before stenting in this lesion subset could
improve the immediate and late clinical outcomes com-
pared with stenting alone. In this study comparing two
strategies for the treatment of SVG aortoostial lesions,
we found no difference in the immediate and late
outcomes after stenting with or without prestent athero-
Table 5. Procedural Results and Clinical Outcome at One Year
Group I
Debulking and Stents
(n 5 133 Patients)
Group II
Stents Alone
(n 5 187 Patients) p Value
In-hospital results
Procedural success (%) 97.8 97.4 0.40
Major hospital complications (%) 2.2 2.6 0.24
Death (%) 0.7 0.5 0.83
Q wave MI (%) 1.5 1.6 0.97
Emergent CABG (%) 0.0 0.5 0.93
Non Q wave MI (%) 18.2 18.5 0.94
Subacute stent thrombosis (%) 2.5 1.9 0.79
Vascular complications (%) 7.4 8.5 0.73
One year follow-up (%)
Death (%) 7.4 10.5 0.33
Q wave MI (%) 1.5 0.5 0.57
Target lesion revascularization (%) 19.4 18.2 0.47
Target lesion CABG (%) 4.3 3.6 0.32
Target lesion PTCA (%) 15.8 14.5 0.72
Any repeat revascularization (%) 23.7 19.9 0.39
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty.
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ablation. Device selection was based on vessel size,
anatomy, preprocedural lesion morphology (lesion eccen-
tricity, ulceration, irregularity, calcification and throm-
bus) and degeneration of the graft. De novo lesions
involving the ostium of the larger (.3 mm) nondegen-
erated graft were treated with directional atherectomy
followed by stent implantation or balloon angioplasty
followed by stent insertion. Lesions located in the ostium
of the smaller vein grafts were treated with excimer laser
angioplasty and stents or stents alone. Due to the
relatively small sample size in each group, there was no
statistical difference in the baseline lesion characteristic.
Overall major in-hospital complications (death, Q wave
MI and CABG) were infrequent in both treatment groups
despite lesion complexity. However, there was a relatively
high frequency of periprocedural non-Q wave MI after both
types of treatment (18.2% in group I and 18.5% in group II,
p 5 0.60). This high prevalence of non-Q wave MI perhaps
represents a very complex subset of lesions in diffusely
diseased SVG grafts. Several reports have indicated an
association between periprocedural CK-MB elevations and
late adverse cardiac events (19,20), and this could also
account for high late mortality in our study. Only a minority
(,5%) of patients was treated with glycoprotein IIb/IIIa
inhibitor, and distal protection devices were not used in this
study.
Stent synergy (prestent atheroablation) approach. The
rationale of this strategy was to test the hypothesis of
whether atheroablation before stenting could facilitate sub-
sequent optimal stent expansion and whether this optimal
stent expansion translates into improved long-term out-
come. Although with this approach we were able to achieve
a larger final MLD (3.43 6 0.76 mm vs. 3.21 6 0.70 mm;
p 5 0.05) and less residual plaque burden (57.6 6 10.69%
vs. 64.9 6 11.05%; p 5 0.01), no impact on the procedural
and late clinical outcome was demonstrated. The most likely
explanation may be that the atheroablation is not sufficient
to have a long-term impact. Compared with the reference
diameter of 3.5 mm, the atheroablative devices create
relatively small lumen (1.7 mm to ,3 mm). This is
illustrated by the relatively large residual plaque burden
(approximately 60%).
Figure 1. Representative angiogram of a 61-year-old patient
reveals severe ostial lesion in the saphenous vein graft to the
diagonal branch of the left anterior descending artery (A, arrows).
Laser catheter positioned across the ostium of the graft (B, arrow).
Figure 1. (continued). After treatment with laser and implantation
of a 4 mm biliary Palmaz-Schatz stent, excellent angiographic
results were achieved (C, arrow).
1566 Ahmed et al. JACC Vol. 35, No. 6, 2000
Debulking and Stenting in Ostial Vein Grafts May 2000:1560–8
Conclusions. This study demonstrates that stent implan-
tation in SVG aortoostial lesions is associated with high
procedural success rate, lower complications and acceptable
one-year follow-up clinical events. As there is no difference
in procedural outcomes, late clinical events and target lesion
revascularization between patients undergoing debulking
before stenting or stenting alone, debulking before stent
implantation may not be necessary.
Study limitations. There are several limitations of our
study. First, only lesions treated with Palmaz-Schatz stents
were included in the analysis, and it is unknown whether
different stent designs may have influenced the clinical
outcome. Second, this study was a retrospective analysis of
the clinical, angiographic and IVUS data from a large group
of consecutively studied patients and, therefore, the results
and conclusions are subject to limitations inherent in all
such reports. Third, IVUS was performed in a majority
(79.4%) of the cases, and the results of this study may not
apply to those cases where IVUS is not used. Fourth, the
clinical follow-up in the matched cohort was truncated at
one year, and long term follow-up may have produced
different results because vein graft failure continues to
develop with time. Finally, the use of different devices and
IVUS guidance was based on operator decision and not on
random assignment; therefore, the strength of the conclu-
sions made with respect to the effect of these variables on
late outcome and TLR is limited. Despite these limitations,
this study provides clinically relevant information about the
impact of different revascularization strategies in patients
with SVG aortoostial lesions.
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